The present invention relates to antibodies that bind to certain oncogenic mutant forms of KRAS. The invention also relates to certain epitopes of oncogenic mutant forms of KRAS. The invention also relates to immunoconjugates and compositions comprising such antibodies. The invention also provides methods of producing such antibodies. The invention further provides the use of such antibodies for therapeutic purposes, for example in the treatment of cancer.

Problem to be solved: An object of the present invention is to obtain medicinal effect that could not be obtained by conventional peptide vaccines that activate and proliferate a CD8-positive CTL by administering a Class II epitope as a peptide vaccine. Solution: The inventors of the present invention have found, as a result of diligent examination on the aforementioned problems, that these problems can be solved by acquiring a peptide having a partial amino acid sequence containing a mutated amino acid of a neoantigen expressed in cancer cells and being an epitope presented by a Class II molecule.

The present invention provides peptides comprising a sequence of X-.sub.6X-.sub.5X-.sub.4X-.sub.3X-.sub.2X-.sub.1X.sub.1PX.sub.3X.sub.4PX.sub.6X.sub.7PGX.sub.10X.sub.11AX.sub.13X.sub.14X.sub.15X.sub.16LX.sub.18X.sub.19X.sub.20X.sub.21X.sub.22X.sub.23LX.sub.25X.sub.26YLX.sub.29X.sub.30X.sub.31X.sub.32 wherein the amino acids X-.sub.6, X-.sub.5, X-.sub.4, X-.sub.3, X-.sub.2, X-.sub.1, X.sub.1, X.sub.3, X.sub.4, X.sub.6, X.sub.7, X.sub.10, X.sub.11, X.sub.13, X.sub.14, X.sub.15, X.sub.16, X.sub.18, X.sub.19, X.sub.20, X.sub.21, X.sub.22, X.sub.25, X.sub.26, X.sub.29, X.sub.30, X.sub.31, and X.sub.32 are as defined herein. The present invention further provides pharmaceutical compositions comprising the peptides and methods of using the peptides for treating proliferative diseases such as cancer which are associated with Ras. Also provided are methods of screening a library of peptide dimers using a peptide dimer display technology.

The present invention provides peptides comprising a sequence of X-.sub.6X-.sub.5X-.sub.4X-.sub.3X-.sub.2X-.sub.1X.sub.1PX.sub.3X.sub.4PX.sub.6X.sub.7PGX.sub.10X.sub.11AX.sub.13X.sub.14X.sub.15X.sub.16LX.sub.18X.sub.19X.sub.20X.sub.21X.sub.22X.sub.23LX.sub.25X.sub.26YLX.sub.29X.sub.30X.sub.31X.sub.32 wherein the amino acids X-.sub.6, X-.sub.5, X-.sub.4, X-.sub.3, X-.sub.2, X-.sub.1, X.sub.1, X.sub.3, X.sub.4, X.sub.6, X.sub.7, X.sub.10, X.sub.11, X.sub.13, X.sub.14, X.sub.15, X.sub.16, X.sub.18, X.sub.19, X.sub.20, X.sub.21, X.sub.22, X.sub.25, X.sub.26, X.sub.29, X.sub.30, X.sub.31, and X.sub.32 are as defined herein. The present invention further provides pharmaceutical compositions comprising the peptides and methods of using the peptides for treating proliferative diseases such as cancer which are associated with Ras. Also provided are methods of screening a library of peptide dimers using a peptide dimer display technology.

Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

The invention relates to a composition and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The composition comprises a recombinant MVA encoding a Tumor Associated Antigen (“TAA”) as well as 4-1BBL and/or CD40L and can be administered to a subject in any suitable manner, including by intravenous and/or intratumoral administration.

The present invention relates to interleukin-2 fusion proteins. More specifically, the invention provides, in part, fusion proteins that include a interleukin-2 protein moiety joined to a Bcl-2 family member protein moiety.

The present invention relates to interleukin-2 fusion proteins. More specifically, the invention provides, in part, fusion proteins that include a interleukin-2 protein moiety joined to a Bcl-2 family member protein moiety.

The present invention relates to a novel cancer-associated biomarker and different applications and uses thereof. More specifically, the invention relates to a novel splice variant of CIP2A denoted as NOCIVA, as well as binding bodies such as probes, amplification primers, and antibodies specific for the same. Also provided are various methods for detecting and prognosing cancer on the basis of said splice variant, and a kit for use in said methods.

The present invention relates to a novel cancer-associated biomarker and different applications and uses thereof. More specifically, the invention relates to a novel splice variant of CIP2A denoted as NOCIVA, as well as binding bodies such as probes, amplification primers, and antibodies specific for the same. Also provided are various methods for detecting and prognosing cancer on the basis of said splice variant, and a kit for use in said methods.